CereVasc today announced that it received an FDA investigational device exemption approval to begin a trial of the eShunt for normal pressure hydrocephalus. The Boston-based company can initiate its pilot trial of the eShunt system in patients with normal pressure hydrocephalus (NPH). The eShunt device offers a minimally invasive treatment with … [Read more...] about CereVasc wins FDA IDE approval to begin eShunt pilot study
Shunts
CereVasc successfully performs first-in-human procedure with eShunt system
CereVasc announced today that it completed the first treatment with its eShunt system for treating communicating hydrocephalus (CH). Boston-based CereVasc touts the eShunt as the first minimally invasive cerebrospinal fluid shunt and delivery technology designed to avoid the need for invasive surgery and extended hospitalization associated with … [Read more...] about CereVasc successfully performs first-in-human procedure with eShunt system
